Abstract
Members of the B7 family costimulate the proliferation of lymphocytes during the initiation and maintenance of antigen-specific humoral and cell-mediated immune responses. While B7-1 and -2 are restricted to lymphoid tissues, and activate naïve T cells, recently identified members including B7-H2 and -H3 are widely expressed on nonlymphoid tissues, and regulate effector lymphocytes in the periphery. B7-H3 has properties that suggested it may display antitumor activity, including the ability to stimulate Th1 and cytotoxic T-cell responses. Here, we test this notion by determining whether intratumoral injection of an expression plasmid encoding a newly described mouse homologue of B7-H3 is able to eradicate EL-4 lymphomas. Intratumoral injection of a mouse B7-H3 pcDNA3 expression plasmid led to complete regression of 50% tumors, or otherwise significantly slowed tumor growth. Mice whose tumors completely regressed resisted a challenge with parental tumor cells, indicating systemic immunity had been generated. B7-H3-mediated antitumor immunity was mediated by CD8+ T and NK cells, with no apparent contribution from CD4+ T cells. In summary, the results indicate that B7-H3 interactions may play a role in regulating cell-mediated immune responses against cancer, and that B7-H3 is a potential therapeutic tool.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chambers CA, Allison JP . Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11: 203–210.
Liang L, Sha WC . The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol 2002; 14: 384–390.
Coyle A, Gutierrez-Ramos J . The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001; 2: 203–209.
Henry J, Miller M, Pontarotti P . Structure and evolution of the extended B7 family. Immunol Today 1999; 20: 285–288.
Yoshinaga SK et al. T cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402: 827–831.
Hutloff A et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397: 263–266.
Freeman G et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027–1034.
Latchman Y et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261–268.
Tseng SY et al. B7-DC a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839–846.
Nishimura H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141–151.
Nishimura H et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319–322.
Chapoval A et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269–274.
Townsend SE, Allison JP . Tumor rejection after direct costimulation of CD8+ T cells by B7 transfected melanoma cells. Science 1993; 259: 368–370.
Chen L et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093–1102.
Baskar S et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc Natl Acad Sci USA 1993; 90: 5687–5690.
Kanwar J, Berg R, Lehnert K, Krissansen GW . Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity. Gene Therapy 1999; 6: 1835–1844.
Sun X et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001; 8: 638–645.
Sun X et al. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Therapy 2001; 8: 719–727.
Kanwar JR, Shen WP, Berg R, Krissansen GW . Effect of survivin antagonists on the growth of established tumors and B7.1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541–1552.
Kanwar JR et al. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1-mediated immunotherapy overcomes immune-resistance and leads to the eradication of large tumors. Cancer Res 2000; 61: 1948–1956.
Sun M et al. Characterization of mouse and human B7-H3 genes. J Immunol 2002; 168: 6294–6297.
Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523–532.
Maeda H, Shiraishi A . TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996; 156: 73–78.
Won J et al. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 1999; 59: 1273–1277.
Tannenbaum CS, Hamilton TA . Immune-inflammatory mechanisms in IFNgamma-mediated antitumor activity. Sem Cancer Biol 2000; 10: 113–123.
Wilson JL et al. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 1999; 163: 4207–4212.
Acknowledgements
This work was supported in part by grants from The Wellcome Trust, the Royal Society of New Zealand, the Health Research Council of New Zealand, and the Maurice and Phyllis Paykel Trust. XS and MV contributed equally to the work. XS is a recipient of a Wellcome Trust Research Leave Fellowship. MV was a recipient of an HRC Junior Award in Health Research.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sun, X., Vale, M., Leung, E. et al. Mouse B7-H3 induces antitumor immunity. Gene Ther 10, 1728–1734 (2003). https://doi.org/10.1038/sj.gt.3302070
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302070
Keywords
This article is cited by
-
Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo
Clinical and Translational Oncology (2022)
-
B7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration
Cell Biochemistry and Biophysics (2021)
-
Dendritic cell-associated B7-H3 suppresses the production of autoantibodies and renal inflammation in a mouse model of systemic lupus erythematosus
Cell Death & Disease (2019)
-
The versatile role of exosomes in cancer progression: diagnostic and therapeutic implications
Cellular Oncology (2018)
-
B7-H3 in tumors: friend or foe for tumor immunity?
Cancer Chemotherapy and Pharmacology (2018)